Premium
Combination effect of PectaSol and Doxorubicin on viability, cell cycle arrest and apoptosis in DU‐145 and LNCaP prostate cancer cell lines
Author(s) -
Tehranian Najmeh,
Sepehri Houri,
Mehdipour Parvin,
Biramijamal Firouzeh,
HosseinNezhad Arash,
Sarrafnejad Abdolfattah,
Hajizadeh Ebrahim
Publication year - 2012
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1042/cbi20110309
Subject(s) - lncap , apoptosis , viability assay , cell cycle , cell cycle checkpoint , doxorubicin , cancer research , cytotoxicity , cell growth , cancer cell , prostate cancer , programmed cell death , biology , chemistry , cancer , medicine , in vitro , chemotherapy , biochemistry
The effect of PectaSol on Dox (Doxorubicin) cytotoxicity in terms of apoptosis and cell cycle changes in PCa (prostate cancer) cell lines (DU‐145 and LNCaP) has been investigated. Combination of PectaSol and Dox resulted in a viability of 29.4 and 32.6% ( P <0.001) in DU‐145 and LNCaP cells. The IC 50 values decreased 1.5‐fold and 1.3‐fold in the DU‐145 and LNCaP cells respectively. In the DU‐145 cells, combination of PectaSol and Dox resulted in a reduction in p27 gene and protein expression ( P <0.001). In LNCaP cells, this combination increased p53, p27 and Bcl‐2 expression. Treatment with both drugs in DU‐145 cells led to an increase in sub‐G 1 arrest (54.6% compared with 12.2% in Dox). In LNCaP cells, combination of the drugs led to an increased in G 2 /M arrest (61.7% compared with 53.6% in Dox). Based on these findings, progressive cytotoxicity effect of Dox and PectaSol together rapidly induce cell death in DU‐145 through apoptosis and in LNCaP cells through cell cycle arrest (G 2 /M arrest).